CRC patients with higher miR-133b expression levels had better overall survival than the group with lower miR-133b expression levels (Figure 7A), while HOXA9 showed the opposite that high expression predicts worse outcome (Figure 7B). Here, HOXA9 is linked to colorectal carcinoma.